Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) has provided an update.
Alphamab Oncology has announced the grant of 1,990,176 award shares under its Restricted Share Award Scheme to three eligible participants, including two executive directors and an employee. This move is part of the company’s strategy to reward and incentivize key personnel, aligning with its remuneration policy and long-term growth objectives. The shares will vest in batches over a period of up to ten years, reflecting the company’s commitment to retaining talent and enhancing its competitive positioning in the oncology sector.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biotechnology company focused on the development and commercialization of innovative cancer therapies. The company is primarily engaged in the research and development of oncology drugs, targeting a global market with a particular emphasis on biologics and antibody-based treatments.
Average Trading Volume: 4,235,882
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.71B
For a thorough assessment of 9966 stock, go to TipRanks’ Stock Analysis page.